Literature DB >> 6361173

Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups.

J B Robbins, R Austrian, C J Lee, S C Rastogi, G Schiffman, J Henrichsen, P H Mäkelä, C V Broome, R R Facklam, R H Tiesjema.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6361173     DOI： 10.1093/infdis/148.6.1136

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  139 in total

1.  Characterization of the type 8 capsular gene cluster of Streptococcus pneumoniae.

Authors:  R Muñoz; M Mollerach; R López; E García
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

Review 2.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

3.  Combinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F.

Authors:  A H Lucas; K D Moulton; V R Tang; D C Reason
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Persistence of two invasive Streptococcus pneumoniae clones of serotypes 1 and 5 in comparison to that of multiple clones of serotypes 6B and 23F among children in southern Israel.

Authors:  N Porat; R Trefler; R Dagan
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

5.  Molecular characterization of Streptococcus pneumoniae type 4, 6B, 8, and 18C capsular polysaccharide gene clusters.

Authors:  S M Jiang; L Wang; P R Reeves
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Repertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.

Authors:  Y Sun; M K Park; J Kim; B Diamond; A Solomon; M H Nahm
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

7.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

9.  Evolution and virulence of serogroup 6 pneumococci on a global scale.

Authors:  D Ashley Robinson; David E Briles; Marilyn J Crain; Susan K Hollingshead
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

10.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.